NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Enterobiome Inc.

Enterobiome Inc.

Private
Goyang-siHealthcare & Life Scienceshttps://enterobiome.com/

Last Round

VC Round

Sep 27, 2024

Est. Valuation

$46.67M

Total Funding Raised

$14.5M

Company Overview

Enterobiome Inc. is a biotechnology company that develops microbiome-based pharmaceutical products and health-functional foods for the treatment of immune diseases, metabolic disorders, and other conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

microbiome therapeuticspharmabioticsmicrobiome drugsgut microbiomeanaerobic bacterianext-gen probioticsdrug discoveryAkkermansia muciniphilahealth-functional foodslive biotherapeutic productsLBPsgut healthbiotech startupclinical trialssupplements

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enterobiome Inc. Comparables

Compare Enterobiome Inc. with similar companies based on industry and business-model similarity.

Enterobiome Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ImmunoBiome Inc.
88%
AtoGen Co., Ltd.
83%
KoBioLabs Inc
79%

Enterobiome Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 27, 2024
Series BJan 1, 2022
Series AJan 12, 2021
SeedJun 1, 2019

Key People

Founding team and executive leadership

Seo Jay

Chief Executive Officer

Executive Team

서재구

CEO

Executive Team

Enterobiome Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2021

    $4.8M round led by Hanwha Investment & Securities

Enterobiome Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enterobiome Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enterobiome Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersGoyang-si
Employee Range13
Year Founded2018
Last FundingSep 27, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.